The AYA Oncology Self-care Movement
The AYA Oncology Self-care Movement: An Influencer-driven Social Media Intervention for Oral Chemotherapy Adherence
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 15 Years to 25 Years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
- Time periods mentioned: 12 weeks
- Procedures mentioned: Questionnaires, Pills, Interviews
Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.
Show the study's own words
- "Across aims, AYAs will then complete a baseline questionnaire (assessing demographics, cancer information, and perceived medication adherence and self-management abilities)."
- "Participants in both groups will be asked to continue using the electronic pill bottle to passively monitor 6-MP adherence over the next five months."
- "For AYAs randomized to the social media condition, the intervention will begin on day 29 and last for 12 weeks."
- "Following the intervention period, all participants will be asked to complete follow-up REDCap surveys of self-management variables at 4-months (T2) and 6-months (T3)."
- "In addition to self-management indices, AYAs from the social media group will complete a questionnaire measure of intervention acceptability at T2."
- "Some AYAs will also be asked to complete an interview about their experiences with the intervention."
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This trial will test the impact of a social media intervention for improving oral chemotherapy adherence among adolescents and young adults (AYAs) with acute lymphoblastic leukemia.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * 15-25 years old * Diagnosed with acute lymphoblastic leukemia (ALL) * Taking 6-mercpatopurine (6-MP) as part of their maintenance treatment with at least 6-months remaining * Be able to speak and read English * Have at least one active social media account (e.g., Instagram, TikTok) or be willing to download a platform for the study * Endorse missing a 6-MP dose in the prior month and/or at least one adherence barrier. Exclusion Criteria: * Cognitive impairments that would limit ability to complete measures, determined by the medical team * Absence of inclusion criteria above.
Study sites (4)
IL
- Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL 60611Alexandra Psihogios, Ph.D. · Study contact · 2409946546 · apsihogios@luriechildrens.orgAlexandra Psihogios, Ph.D. · Principal investigatorMore trials in Chicago
- Northwestern University · Chicago, IL 60611Alexandra Psihogios, Ph.D. · Study contact · 240-994-6546 · alex.psihogios@northwestern.eduAlexandra Psihogos, PhD · Sub-investigatorBetina Yanez, Ph.D. · Principal investigatorMore trials in Chicago
PA
- The Children's Hospital of Philadelphia · Philadelphia, PA 19104Lisa Schwartz, PhD · Study contact · 267-426-0355 · schwartzl@chop.eduLisa Schwartz, PhD · Principal investigatorMore trials in Philadelphia
TX
- MD Anderson Cancer Center · Houston, TX 77030Michael Roth, MD · Study contact · 1-877-632-6789 · MRoth1@MDAnderson.orgMichael Roth, MD · Principal investigatorMore trials in Houston